Clinical-stage pharmaceutical company LTR Pharma (ASX:LTP) has moved to broaden its innovation platform, securing a one-third equity stake in LevOmega at no cost to shareholders.
The deal gives LTR Pharma a foothold in the multi-billion-dollar omega-3 market while complementing its core focus on rapid-acting intranasal therapies.
LevOmega, in collaboration with Levur and Green Blue Health, is developing pharmaceutical-grade, nature-identical omega-3 oils through a biotechnology platform designed to overcome the challenges of traditional marine-based sources. A formal R&D and licensing agreement between LevOmega and Levur is now in place to accelerate product development and commercialisation.
For LTR Pharma, the partnership is as much about strategy as science. Omega-3 oils are widely recognised for their cardiovascular and anti-inflammatory health benefits, but global demand for EPA and DHA is already outstripping the limits of sustainable marine supply. Overfishing, pollution, and environmental degradation have made fish-derived omega-3 increasingly difficult to source reliably.
LevOmega aims to fill this gap by creating consistent, scalable, and high-purity omega-3 ingredients that can be used in both pharmaceutical and nutritional products. The company’s next steps include validating its technology, producing pilot-scale volumes, and preparing for commercial launch. Ultimately, the goal is to provide manufacturers of pharmaceuticals, nutraceuticals, and functional foods with a new, sustainable supply chain for omega-3.
This expansion adds another dimension to LTR Pharma’s pipeline, which already includes its flagship intranasal therapies SPONTAN and ROXUS for erectile dysfunction and OROFLOW, a spray in development for oesophageal motility disorders.